Alkermes (ALKS) Income from Continuing Operations (2010 - 2026)
Alkermes (ALKS) reported Income from Continuing Operations of 66526000.0 for Q1 2026, down 395.82% year-over-year from 22489000.0 in Q1 2025, and down 234.69% quarter-over-quarter from 49391000.0 in Q4 2025.
Alkermes (ALKS) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Income from Continuing Operations data on file, last reported at 66526000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 66526000.0, down 395.82% year-over-year; the trailing twelve-month figure through Mar 2026 was 152749000.0 (down 57.05% YoY), and the FY2025 annual result was 241664000.0, down 35.06% from the prior year.
- Income from Continuing Operations eased to 66526000.0 in Q1 2026 per ALKS's latest filing, from 49391000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 279129000.0 in Q2 2023 and troughed at 66526000.0 in Q1 2026.
- A 5-year average of 55054411.76 and a median of 63173000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations sank 1374.79% in 2022, then jumped 1026.23% in 2023.
- A 5-year view of Income from Continuing Operations shows it stood at 96861000.0 in 2022, then slumped by 34.78% to 63173000.0 in 2023, then surged by 130.7% to 145737000.0 in 2024, then slumped by 66.11% to 49391000.0 in 2025, then tumbled by 234.69% to 66526000.0 in 2026.
- Business Quant data shows ALKS's Income from Continuing Operations at 66526000.0 in Q1 2026, 49391000.0 in Q4 2025, and 82745000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 52.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.53 Mn |
| Dec 31, 2025 | 49.39 Mn |
| Sep 30, 2025 | 82.75 Mn |
| Jun 30, 2025 | 87.14 Mn |
| Mar 31, 2025 | 22.49 Mn |
| Dec 31, 2024 | 145.74 Mn |
| Sep 30, 2024 | 92.80 Mn |
| Jun 30, 2024 | 94.62 Mn |
| Mar 31, 2024 | 38.91 Mn |
| Dec 31, 2023 | 63.17 Mn |
| Sep 30, 2023 | 91.51 Mn |
| Jun 30, 2023 | 279.13 Mn |
| Mar 31, 2023 | -12.03 Mn |
| Dec 31, 2022 | 96.86 Mn |
| Sep 30, 2022 | -63.97 Mn |
| Jun 30, 2022 | -30.14 Mn |
| Mar 31, 2022 | -35.90 Mn |
| Dec 31, 2021 | 135.97 Mn |
| Sep 30, 2021 | -28.99 Mn |
| Jun 30, 2021 | 2.36 Mn |